New regulations aim to fast-track safer medicines, boost drug innovation, and clean up online sales.
China has rolled out revised drug administration regulations to encourage pharmaceutical innovation, tighten oversight of online medicine sales, and strengthen drug safety controls.
The updated rules—signed into law by Premier Li Qiang—will take effect May 15 and overhaul key parts of the country’s drug system, from research and clinical trials to manufacturing, distribution and safety checks.
At the heart of the changes is a clinical value-driven approach to drug development, with faster review channels for promising new medicines and clearer rules for trials, re-registration, and switching drugs from prescription to over-the-counter.
To reward innovation, China is offering market exclusivity for certain pediatric and rare-disease drugs, plus data protection for medicines with new chemical ingredients.
The regulations also tighten control of online drug sales, increase accountability for e-commerce platforms, and sharpen supervision of manufacturing—especially for traditional Chinese medicine products.
On safety, the rules spell out stricter inspections, clearer testing procedures, and tougher penalties, while allowing companies to request re-tests if they dispute results.
China wants faster innovation, safer drugs, and stronger oversight—all at once.
Leave a comment